COMMUNIQUÉS West-GlobeNewswire

Arvinas to Present at Two Protein Degradation Conferences
23/10/2018
NEW HAVEN, Conn., Oct. 23, 2018 (GLOBE NEWSWIRE) -- Arvinas Inc. (Nasdaq: ARVN), a biotechnology company creating a new class of drugs based on protein degradation, today announced it will be presenting at two upcoming [...]
Pain Therapeutics Invites you to Join a Conference Call on Third Quarter 2018 Financial Results
23/10/2018
Call to be held on Monday, October 29th at 4:30 p.m. Eastern Time AUSTIN, Texas, Oct. 23, 2018 (GLOBE NEWSWIRE) -- Pain Therapeutics, Inc. (Nasdaq:PTIE), a biopharmaceutical company, announced today it will release [...]
Elite Pharmaceuticals Reports Positive Topline Results from a Pivotal Bioequivalence Study
23/10/2018
NORTHVALE, N.J., Oct. 23, 2018 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the “Company") (OTCBB: ELTP), a specialty pharmaceutical company developing abuse-deterrent opioids and niche generic products, [...]
Canada House Wellness Group Will Hold Annual General Meeting on October 30th
23/10/2018
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES TORONTO, Oct. 23, 2018 (GLOBE NEWSWIRE) -- Canada House Wellness Group Inc (“Canada House” or the “Company”) (CSE: CHV) would like to [...]
KemPharm and twoXAR Announce Technology Collaboration to Develop Prodrug-Based Therapies for Multiple Indications
23/10/2018
Drug Development Approach Combines twoXAR’s Artificial-Intelligence-Driven Drug Discovery Technology with KemPharm’s LAT TM Prodrug Technology CORALVILLE, Iowa, Oct. 23, 2018 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ: [...]
Selecta Biosciences Presents New Interim Data from Phase 2 Trial of SEL-212, in Development for Chronic Severe Gout, at ACR 2018
23/10/2018
Interim analysis indicates serum uric acid (SUA) control has been maintained into months four and five with once monthly combination treatment, SUA control projected to be 66% at end of study period Patient imaging has [...]
IMV Inc. to Announce Third Quarter 2018 Financial Results and Host Earnings Call on November 2, 2018
23/10/2018
DARTMOUTH, Nova Scotia, Oct. 23, 2018 (GLOBE NEWSWIRE) -- IMV Inc. (“IMV” or the “Corporation”) (Nasdaq: IMV; TSX: IMV), a clinical stage immunotherapy company, announced today that it will hold a conference call and [...]
Myriad Announces Publication of Foresight™ Carrier Screen Clinical Utility Study in Genetics in Medicine
23/10/2018
Large Study Demonstrates that Expanded Carrier Screening Informs Couples’ Reproductive Choices and Pregnancy Management SALT LAKE CITY, Oct. 23, 2018 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a global [...]
Resonant Releases Details of its Breakthrough XBAR Resonator Technology for 5G Mobile Devices
23/10/2018
GOLETA, Calif., Oct. 23, 2018 (GLOBE NEWSWIRE) -- Resonant Inc. (NASDAQ: RESN), a leader in transforming the way radio frequency, or RF, front-ends are being designed and delivered for wireless devices, today released [...]
Aptose to Release Third Quarter Ended September 30, 2018 Financial Results on November 6, 2018
23/10/2018
Conference Call to Be Held Wednesday, November 7, 2018 SAN DIEGO and TORONTO, Oct. 23, 2018 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (NASDAQ: APTO; TSX: APS), a clinical-stage company developing highly differentiated [...]
Tonix Pharmaceuticals to Present at the Dawson James Securities Small Cap Growth Conference
23/10/2018
NEW YORK, Oct. 23, 2018 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix) announced today that Seth Lederman, M.D., President and Chief Executive Officer of Tonix, will present and host [...]
Imprimis Pharmaceuticals’ Subsidiary Melt Pharmaceuticals Initiates Clinical Development Program for its Patented Non-Opioid and Non-Invasive MK Melt™ Conscious Sedation Drug Candidate
23/10/2018
FDA Grants Pre-IND Meeting; Two Investigator-led Studies on Melt Formulations to Commence in Q4 SAN DIEGO, Oct. 23, 2018 (GLOBE NEWSWIRE) -- Melt Pharmaceuticals, a subsidiary of Imprimis Pharmaceuticals, Inc. (NASDAQ: [...]
Beyondspring Provides Operational Update and Second-Quarter 2018 Financial Results
23/10/2018
- Reported Top Line Positive Efficacy and Safety Data from Phase 2 Study 106 Evaluating Plinabulin in Combination With Neulasta for Chemotherapy-Induced Neutropenia (CIN) Prevention - On Track to Report Interim Data [...]
Intra-Cellular Therapies Announces Favorable Safety Profile for ITI-214 in a Phase 1/2 Clinical Trial in Patients with Parkinson’s Disease
23/10/2018
Results show ITI-214 is associated with clinical signs consistent with improvements in motor symptoms and dyskinesias NEW YORK, Oct. 23, 2018 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) today [...]
CureVac Announces First Study Participant Enrolled in Phase I Clinical Trial Testing Prophylactic mRNA Rabies Vaccine
23/10/2018
Trial to provide first-in-human data for CureVac’s novel mRNA-based intramuscular rabies vaccine TÜBINGEN, Germany and BOSTON, Oct. 23, 2018 (GLOBE NEWSWIRE) -- CureVac AG, a fully integrated biopharmaceutical company [...]
XORTX Announces Revision to Polycystic Kidney Disease Clinical Development Plan
23/10/2018
● Shorter Path to XRx-008 Marketing Approval ● CALGARY, Alberta, Oct. 23, 2018 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (" XORTX " or the “ Company ”) (CSE:XRX; OTCQB:XRTXF), a biopharmaceutical company focused on [...]
NeoGenomics Signs Definitive Agreement to Acquire Genoptix
23/10/2018
FT. MYERS, Fla., Oct. 23, 2018 (GLOBE NEWSWIRE) -- NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of cancer-focused genetic testing services, announced today that it has entered into a definitive agreement to [...]
Cara Therapeutics Appoints Joana Goncalves, M.D., as Chief Medical Officer
23/10/2018
- Former VP of Medical Affairs for Dermatology at Celgene to lead development of KORSUVA™ in dermatological conditions - STAMFORD, Conn., Oct. 23, 2018 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a [...]
BeyondSpring’s Lead Asset, Plinabulin for the Prevention of Chemotherapy-Induced Neutropenia, Has the Potential to Positively Impact Tumor Microenvironment
23/10/2018
Data Demonstrating Plinabulin’s Immune-Enhancing Potential Presented at European Society for Medical Oncology (ESMO) Congress NEW YORK, Oct. 23, 2018 (GLOBE NEWSWIRE) -- BeyondSpring Inc . (NASDAQ: BYSI), a global, [...]

Pages